Introduction
============

Despite significant advances in the basic understanding of tumor pathogenesis, improvement in surgical techniques and new adjunct treatment, the median overall survival rate of patients with glioblastoma (GB) has increased only by 3.3 months (from 11.3 to 14.6 months) until 2010 ([@b1-ol-0-0-9397],[@b2-ol-0-0-9397]) with a long-term survival rate above three years of only 3 to 5% ([@b3-ol-0-0-9397]). During the past decade, the consistent implementation of surgical re-resection in recurrent GB has helped to improve this devastating figure resulting in up to 25 months of overall survival rate, and 11.9 months following the first resection ([@b4-ol-0-0-9397]). The main predictive factors of survival are tumor localization in eloquent areas of the brain and the functional performance and tumor volume of the patient.

In GB, a small cell population with stem cell-like properties is resistant to chemotherapy. These cells exhibit unique energy metabolic characteristics ([@b5-ol-0-0-9397]), including low mitochondrial respiration and a preference for hypoxia, to maintain their tumor-forming capacity ([@b6-ol-0-0-9397]). *In vitro*, hypoxia promotes the survival of these clonogenic cancer stem cells ([@b7-ol-0-0-9397]) and inhibits their differentiation even if the cultures are returned to normoxic conditions ([@b8-ol-0-0-9397]). Furthermore, approximately half of all human GB respond to hypoxia by inducing c-Met, with subsequent enhancement of tumor cell migration and invasion ([@b9-ol-0-0-9397]).

Treatment strategies utilizing reactive oxygen (O~2~) species induce cell death by autophagy and apoptosis in glioma cell cultures ([@b10-ol-0-0-9397]). Employing positron emission tomography (PET) or advanced magnetic resonance imaging (MRI) techniques such as MR spectroscopy enable the monitoring of local O~2~ levels ([@b11-ol-0-0-9397]). The intracellular *in vivo* oxymetry in rats implanted with the aggressive glioma cell line 9L demonstrates the preference for low tumor pO~2~ levels around 45 mmHg ([@b12-ol-0-0-9397]). Treatment with bischloroethylnitrosourea (BCNU) resulted in an immediate and significant increase in pO~2~ up to 140 mmHg ([@b12-ol-0-0-9397]). These anti-tumorigenic properties of oxygen are accompanied by its key role in regulating the immunogenicity of primary human glioma cells ([@b13-ol-0-0-9397]). Furthermore, the application of O~2~ plus ozone (O~3~) in two different human neuroblastoma cell lines (SK-N-SH and SK-N-DZ) induced cell growth inhibition at G~2~ phase and cell cycle perturbation in both cell lines ([@b14-ol-0-0-9397]).

Ozone is a gas that is produced endogenously by granulocytes. In the presence of an electron donor, reactive O~2~ species are produced, particularly hydrogen peroxide ([@b15-ol-0-0-9397]). Clinical O~3~ application has resulted in improved wound healing ([@b16-ol-0-0-9397],[@b17-ol-0-0-9397]), and the improvement of radiation-induced proctitis ([@b18-ol-0-0-9397]) and cystis ([@b19-ol-0-0-9397]), as well as the improvement of osteonecrosis ([@b20-ol-0-0-9397]--[@b22-ol-0-0-9397]). The toxicity of inhaled O~3~ can be reduced by applying the gas for a calculated period and at lower doses ([@b23-ol-0-0-9397]--[@b25-ol-0-0-9397]) although certain genetic variance in the O~3~ response exist ([@b26-ol-0-0-9397]). However, O~3~ acts antineoplastically in the presence of carcinogens if administered by inhalation ([@b27-ol-0-0-9397],[@b28-ol-0-0-9397]), intra-vesicular ([@b29-ol-0-0-9397]) or intra-peritoneal ([@b30-ol-0-0-9397],[@b31-ol-0-0-9397]) instillation. Since O~3~ stimulates the release of immunoactive cytokines ([@b32-ol-0-0-9397]), these effects are more likely to be the result of an immune-mediated reaction rather than being a direct consequence of administration ([@b33-ol-0-0-9397]).

Studies have emphasized that O~3~ therapy can be considered a serious adjuvant therapy in oncological patients receiving radiochemotherapy ([@b34-ol-0-0-9397]). The present study reports data from the off-label application of O~2~-O~3~ into the tumor vicinity of GB following surgery in a limited series of patients. In addition, the results of a systematic literature search on O~3~ treatment following surgery for malignancies are presented.

Materials and methods
=====================

Between January 2012 and December 2013, patients diagnosed with GB at the Klinikum Amberg were offered an intra-tumoral treatment with O~2~-O~3~ extending the standard therapy as determined by the local tumor board. Following extensive information about their options and the possible side effects of the treatment, five patients provided their informed consent, and the ethical committee of the Bavarian National Medical Association approved the study, based on the Helsinki Declaration of 1964, revised 2013 (EK-Nr. 2013-125). Informed consent included publication of the case report and any accompanying images. Part of the illustrative case was presented as a poster on the Brain Tumor Meeting May 2013 in Berlin.

### Treatment

Together with the re-resection in recurrent GB, a Rickham reservoir was implanted with the tip ending in the middle of the resection area. The exact catheter localization and the extent of tumor resection were confirmed by an early (\<72 h post-operatively) contrast-enhanced MRI. Subsequently, five ml of O~2~-O~3~ were applied monthly through the reservoir at a concentration of 40 µg O~3~ per ml.

The standard adjuvant therapy following the initial surgery for GB consisted of radiotherapy with a local boost and chemotherapy according to Stupp *et al* ([@b2-ol-0-0-9397]); 75 mg/m^2^ body surface temozolomide followed by cycles with 150 mg/m^2^ body surface, five days per week for the irradiation period, followed by a three week off/one week on schedule. Following progression or recurrence and re-section, the patients were switched to PCV chemotherapy (procarbacine 60 mg/m^2^ day 8 to 21, CCNU 100 mg/m^2^ day and vincristine 1.4 mg/m^2^ day 8+29).

### Histological assessment

Tumor biopsies at primary resection and recurrence(s) were evaluated by an experienced neuropathologist and classified according to the criteria of the WHO 2007 classification of tumors of the central nervous system. Prior to publication, the histological results were reviewed and adapted to the current WHO classification of 2016 ([@b35-ol-0-0-9397]). The standard work-up for diagnostics comprised routine histological stains, immunohistochemistry, including the p53 (BP53-12) and Ki-67 (Mib-1) antigens, and molecular diagnostics for O-6-methylguanine-DNA-methyltransferase (*MGMT*) promoter methylation and isocitrate dehydrogenase (*IDH*) *1/2* mutations. Additionally, immunohistochemistry for hypoxia-inducible factor (HIF)-1α and HIF-2α was performed for investigative purposes ([Fig. 1](#f1-ol-0-0-9397){ref-type="fig"}). Immunohistochemistry on formalin-fixed and paraffin-embedded tissue samples was performed as described previously ([@b36-ol-0-0-9397]). In brief, 5-mm sections were cut and slides were deparaffinized and, following microwave antigen retrieval, stained using the EnVision+ Dual Link System-HRP (DAB+; K4065; Dako; Agilent Technologies GmbH, Waldbronn, Germany) according to the manufacturer\'s protocol. Anti-HIF-1α (NB100-123; Novus Biologicals, Ltd., Cambridge, UK) and anti HIF-2α ha (NB100-122; Novus Biologicals, Ltd.) primary antibodies were used at 1:50 in phosphate buffered saline supplemented with 1% bovine serum albumin. Pre-treatment for antigen retrieval was not applied.

Magnetic resonance tumor volumetry. Volumetric analysis was performed on a GE Advantage Workstation (GE Healthcare Life Sciences, Little Chalfont, UK; version 4.7, Operation System 2.0 on a HELiOS 6.6.1 subsystem) by a radiologist. Tumor size and volume were calculated by semi-automated contouring of tumor borders on each T1 weighted-slice (post gadolinium) in cm^3^ and maximum 2D diameter in mm, as outlined in [Fig. 2](#f2-ol-0-0-9397){ref-type="fig"}. Slice thickness was 1 and 5 mm, dependent on the subsequent protocols of MRI examination sequences applied between January 2012 and July 2017. Enhancing areas were considered as tumor with the exception of obvious vessels, artifacts or postoperative resection defects.

### Statistical analysis

Dichotomous or categorical parameters are presented in frequencies and percentages. Metric variables are provided as median and range. Statistical analyses were performed using SPSS version 21 (IBM Corp., Armonk, NY, USA).

### Systematic literature search

A systematic literature search was performed for observational and clinical studies utilizing an O~3~ treatment for malignancies. Studies published between 01/01/1987 and 01/12/2017 were included, with no limitation regarding study type and sample unit (observational or experimental, animal or patient, *in vitro* or *in vivo*). The retrieval of studies was performed in PubMed using the combined filter and Medical Subject Headings (MeSH) term: \['Ozone/surgery' (Mesh) OR 'Ozone/therapeutic use' (Mesh) OR 'Ozone/therapy' (Mesh)) AND 'Neoplasms' (Mesh)\] The records were screened based on title and abstract independently. Finally, the remaining records were evaluated by reading the full-text papers. All relevant characteristics (study type, disease, route of O~3~ application, unit of analysis, sample size and main findings) reported in the studies were extracted into an evidence table.

Results
=======

The demographic and disease-related characteristics are summarized in [Table I](#tI-ol-0-0-9397){ref-type="table"}. The patient group comprised two women and three men with a median age of 48 years at diagnosis (range 31 to 68 years), the Karnofsky score ([@b37-ol-0-0-9397]) was 80% (range 50 to 90%).

### Primary treatment/initial surgery

In two patients the diagnosis was established following a biopsy, in two patients following a partial resection. In one patient the initial resection was complete and at her request the O~2~-O~3~ therapy was started following diagnosis.

In four out of five patients molecular neuropathology was *IDH* wild-type GB; in the youngest patient the GB exhibited an *IDH* mutation corresponding to (secondary) GB, *IDH*-mutant. The *MGMT* promoter methylation status ranged between \<3 and 25%. The median Ki67 proliferation index was 30% (range 20 to 40%), and the median nuclear score for p53 positivity was 20% (range 0 to 75%).

Of the five patients, four received a radiotherapy with a median of 49 Gy (range, 46 to 50 Gy) accompanied by a local boost of 11 Gy (range, 10 to 14 Gy). In all patients, the initial chemotherapy was started with temozolomide according to Stupp *et al* ([@b2-ol-0-0-9397]).

### Surgery for first recurrence/progression: Further treatment

The patient who insisted on receiving the O~2~-O~3~ treatment following the initial diagnosis remains in remission. In the other four patients, the first recurrence occurred in a median time of five months (range, 4 to 9 months). Together with the re-resection in recurrent GB, a Rickham reservoir for O~2~-O~3~ application was implanted. Five milliliter of O~2~-O~3~ were applied monthly through the reservoir at a concentration of 40 µg O~3~ per ml. The chemotherapy was changed in three out of four patients to PCV; one patient refused further chemotherapy.

### Overall survival and survival following initiation of ozone treatment

The patients received a median of 27 (range, 3 to 44) O~2~-O~3~ applications. The overall median survival rate was 40 months (range, 16 to 53 months). The median survival rate following the first recurrence subsequent to the initiation of the O~2~-O~3~ treatment was 34 months (range, 12 to 53 months). The progression-free survival rate was positively associated with a more extensive surgical re-resection (P=0.021), while the tumor volume was negatively correlated (P=0.027).

In one patient, a local infection occurred resulting in temporary removal of the reservoir. In another patient, a hemorrhage in the tumor vicinity around the catheter four months following the implantation necessitated the temporary removal of the reservoir. Based on a total of 115 O~2~-O~3~ applications in five patients, the complication rate per application was 1.7%.

### Illustrative case

A 59-year-old male patient developed a seizure with a persisting hemiparesis. MRI demonstrated a contrast-enhancing lesion in the motor cortex (10.5 cm^3^; [Fig. 3A](#f3-ol-0-0-9397){ref-type="fig"}). The histological examination confirmed a GB, *IDH* wild-type with a Ki-67 proliferation rate of 20% and no relevant *MGMT* promoter methylation ([Fig. 1A](#f1-ol-0-0-9397){ref-type="fig"}). The patient was treated with radiochemotherapy (50 Gy with local boost of 10 Gy), temozolomide at 75 mg/m^2^ body surface for four weeks, followed by one three weeks off and one cycle at 150 mg/m^2^. The symptoms worsened and a tumor progression was evident at six months with a volume of 29.3 cm^3^ ([Fig. 3B](#f3-ol-0-0-9397){ref-type="fig"}). At the time of tumor resection, a catheter connected to a reservoir was placed in the area of the former tumor cavity ([Fig. 3C](#f3-ol-0-0-9397){ref-type="fig"}). Histology was performed and again demonstrated pleomorphic astrocytic tumor cells and fibroid changes of tumor vessels as a probable therapy-induced alteration ([Fig. 1B](#f1-ol-0-0-9397){ref-type="fig"}). In addition, HIF-2α staining could be observed ([Fig. 1E](#f1-ol-0-0-9397){ref-type="fig"}). O~2~-O~3~ treatment was employed monthly together with a second-line PCV chemotherapy. Then, 13 months following surgery, the catheter was removed due to a local infection accompanied by seizures. The tissue demonstrated reactive and resorptive changes with an accumulation of macrophages ([Fig. 1C](#f1-ol-0-0-9397){ref-type="fig"}). Next, six weeks later, the catheter was re-implanted and the intra-tumoral O~2~-O~3~ treatment was resumed together with the PCV chemotherapy. The patient returned to work and was in a stable neurological condition for almost 40 months. However, paresis of the arm worsened and MRI demonstrated tumor progression. A second re-section was performed, and presented with the histology of a full-blown cell-rich tumor recurrence ([Fig. 1D](#f1-ol-0-0-9397){ref-type="fig"}) but with lowered HIF-2α immunostaining ([Fig. 1F](#f1-ol-0-0-9397){ref-type="fig"}) compared with the first recurrence and the situation prior to O~2~-O~3~ treatment. Comparing the two time points, no differences could be observed in HIF-1α staining. The patient died 40 months after the initial diagnosis, and 33 months following the initiation of O~2~-O~3~ treatment. Another illustrative case is depicted in [Fig. 4](#f4-ol-0-0-9397){ref-type="fig"}. This patient is still alive, more than 4 years after the diagnosis GB.

### Findings from the literature search

The systematic literature search revealed 79 scientific studies. Following the screening of titles and abstracts, 20 articles fulfilled the criteria for eligibility. In three cases, no English full-text articles were available. Finally, a total of seven clinical and ten basic research studies met the eligibility criteria applied to the studies. Data extracted from these studies are shown in [Table II](#tII-ol-0-0-9397){ref-type="table"}.

All cohorts/samples were independent and no overlap of included individuals could be identified. Overall, the sample sizes of the clinical studies detected by the literature search ranged from case reports to a prospective phase I--II study including one to 24 patients. The basic research studies adopted the guidelines for the care and use of animals and included 20 to more than 100 animals.

Discussion
==========

The rationale to perform an individual off-label treatment in GB patients was three-fold: There was i) *in vitro* and *in vivo* evidence for a preference for hypoxia in GB, ii) *in vitro* and *in vivo* evidence for the treatment efficacy of hyperoxia generating reactive O~2~ species in GB, and iii) *in vivo* evidence for the treatment effect of O~3~ in stimulating the immune system in other types of cancer ([@b31-ol-0-0-9397],[@b33-ol-0-0-9397]).

Tumor cells, particularly those with stem cell-like properties, exhibit a preference for hypoxia ([@b6-ol-0-0-9397],[@b12-ol-0-0-9397]). Therefore the intra-tumoral application of O~2~ was aimed at establishing normoxia, thereby inhibiting proliferation and migration ([@b9-ol-0-0-9397]) in addition to promoting differentiation ([@b5-ol-0-0-9397],[@b8-ol-0-0-9397]). Whether this target was accomplished, was not verified. Five ml of O~2~-O~3~ were applied intra-tumorally at a concentration of 40 µg ozone per ml once per month. While direct intracellular oxymetry can be utilized in basic research models, the measurement of tissue O~2~ levels in the clinical setting is restricted to advanced and not readily available techniques such as PET or MR spectroscopy ([@b11-ol-0-0-9397]).

HIFs are transcription factors that respond to decreases in available O~2~ in the cellular environment, or hypoxia. HIF-1 consists of an O~2~-sensitive α-subunit and a constitutively expressed β-subunit, and belongs to a family of transcription factors \[PER/aryl hydrocarbon receptor nuclear translocator (ARNT)/single minded (SIM)\] ([@b38-ol-0-0-9397]--[@b40-ol-0-0-9397]). HIF-1α facilitates, together with HIF-2α, O~2~ delivery and cellular adaptation to hypoxia by stimulating multiple biological processes, including erythropoesis, angiogenesis and anaerobic glucose metabolism ([@b41-ol-0-0-9397]).

Histologically, following the intra-tumoral O~2~-O~3~ application mainly reactive and resorptive changes were identified ([Fig. 1C](#f1-ol-0-0-9397){ref-type="fig"}). Notably, while relevant HIF-1α staining was not present prior to or following the intra-tumoral O~2~-O~3~ application, the HIF-2α expression (particularly in tumor blood vessels) was higher under the hypoxic conditions prior to, compared with following, the treatment ([Fig. 1E and F](#f1-ol-0-0-9397){ref-type="fig"}).

Treatment strategies utilizing reactive O~2~ species in glioma cell cultures have been demonstrated to induce cell death by autophagy and apoptosis ([@b10-ol-0-0-9397]) or at least cell growth inhibition ([@b14-ol-0-0-9397]). Histologically, the present illustrative case identified mainly reactive and resorptive changes following the intra-tumoral O~2~-O~3~ application for a long time period. Only single scattered pleomorphic astrocytic tumor cells could be detected ([Fig. 1C](#f1-ol-0-0-9397){ref-type="fig"}).

O~3~, a gas that is produced endogenously by granulocytes, induces the generation of reactive O~2~ species, stimulates the release of immunoactive cytokines ([@b12-ol-0-0-9397]) and regulates immunogenicity of human glioma cells ([@b13-ol-0-0-9397]). The intra-peritoneal insufflation of O~2~-O~3~ resulted in a tumoricidal immune response in experimental head and neck squamous carcinoma ([@b32-ol-0-0-9397]) with subsequent complete tumor remission ([@b31-ol-0-0-9397]). Oxidative stress converts the immune response from a tumor permissive to a tumoricidal one, probably through the stimulation of systemic T cells, resident macrophages and dendritic cells ([@b32-ol-0-0-9397]).

Human natural killer cells as part of a systemic immune response are most likely at least in part, responsible for the absence of metastases in GB patients ([@b42-ol-0-0-9397]). The exposure of peripheral blood mononuclear cells to a single dose of 1 µg/ml O~3~ increased the numbers of CD3-CD16+/56+ natural killer cells *in vitro* ([@b43-ol-0-0-9397]). In human GB tissue of long-term (\>36 months) survivors, the number of CD 8, CD 20, CD 25 and CD 95 positive lymphocytes was significantly increased compared with short-term (\<1 year) survivors. Therefore, the O~2~-O~3~ application in GB may act as an immunotherapy through the enhancement of human natural killer cells. Histologically, in this context an accumulation of macrophages was identified that immunohistochemically stained for the CD68 (PGM1) antigen following the intra-tumoral O~2~-O~3~ application in our illustrative case ([Fig. 1C](#f1-ol-0-0-9397){ref-type="fig"}).

The intra-peritoneal application of 1 ml O~3~ at 20 or 40 µg/ml into the peritoneal cavity of mice has been performed without side effects in a control group confirming thereby the safety of the selected concentration ([@b30-ol-0-0-9397]). Andreula *et al* ([@b44-ol-0-0-9397]) safely injected four ml O~3~ at 27 µg/ml into the lumbar disc and periganglionic in 600 patients with clinical signs of lumbar disk nerve root compression. The present study applied five ml O~3~ at 40 µg/ml into the tumor cavity and could not identify any direct cell damage or necrosis around the cavity histologically. Nevertheless, the safety of this application has to be confirmed by cell culture of normal CNS tissue and glioma cells in addition to *in vivo* studies.

The median overall survival rate in our series comprising of five patients was 40 months. Since in one patient the O~2~-O~3~ treatment was started following diagnosis, the median survival following recurrence was 30.5 months (range, 12 to 37 months) in the remaining four patients. These data outperform previously published data ([@b3-ol-0-0-9397]) and the data from a recent multicenter trial including 505 patients from 20 institutions undergoing re-resection in recurrent GB ([@b4-ol-0-0-9397]). In that multicenter study, the median overall survival rate was 25 months and 11.9 months following the first resection. Furthermore, one of the patients in the present study treated with local O~2~-O~3~ in addition to the standard treatment following initial surgery remains alive, 53 months following the diagnosis of GB ([Fig. 4A-C](#f4-ol-0-0-9397){ref-type="fig"}). The patients in our series did not differ substantially with regard to known prognostic factors: The median age at diagnosis was 48 years (range, 31 to 68 years), the median Karnofsky score at presentation 80% (range, 50 to 90%), the median proliferation index 30% (range, 20 to 40%) and the median quantitative *MGMT* promoter methylation was 5% (range, 3 to 25%).

However, the authors are aware that a study focusing on long-term survivors following GB presented even better data ([@b45-ol-0-0-9397]). That study retrospectively identified 50 long-term GB survivors (\>36 months). In this selected cohort, the median progression-free survival rate was 25.4 months (range, 2.3 to 97.8 months) compared with six months (range, 4 to 52 months) in our series, and the overall survival rate of long-term survivors was 55.9 months (range, 38.2 to 98.6 months) compared with 40 months (range, 16 to 52 months) in our series.

The authors are aware of several limitations of the present study. The exact dose and the timing of the application were based on estimates and patient comfort. Optimization of both should be performed either in a basic research setting utilizing tissue oxymetry or mapping brain tissue O~2~ saturation in the clinical setting with PET or MRI. Furthermore, this off-label case series should be transferred into a clinical trial.

Taken together, the overall survival rate of our patient series is longer than obtained in an unselected multicenter study. Taking a closer look at a long-term GB survivor cohort ([@b44-ol-0-0-9397]), both progression-free survival and overall survival rate are slightly shorter. These results and the existing evidence revealed by the systematic literature search highlighted that O~3~ therapy could be considered a viable adjuvant therapy in oncological patients receiving radiochemotherapy ([@b34-ol-0-0-9397]). The case series of the present study indicated the potential benefit and efficacy of intra-tumoral O~2~-O~3~ application following surgery for GB. Following this descriptive approach, further observational and experimental research is warranted to elucidate cellular and systemic effects, in addition to ensuring safety by applying inference statistical analyses based on an appropriate sample size.

Part of the illustrative case was presented as a poster on the Brain Tumor Meeting May 2013 in Berlin (abstract no. 36).
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![(A) The initial stereotactic biopsy showed a pleomorphic astrocytic tumor with focal necrosis (insert) corresponding to glioblastoma (WHO grade IV). (B) Also in the first recurrence (six months later) pleomorphic astrocytic tumor cells were present. Additionally, tumor vessels exhibited fibroid changes most likely as a therapy-induced alteration. (C) The first resection after application of O~2~-O~3~ showed CNS tissue with mainly reactive and resorptive changes. Note accumulation of macrophages (black arrowheads) that stain immunohistochemically for the CD68 (PGM1) antigen (insert). Only single scattered pleomorphic astrocytic (tumor) cells can be detected (white arrow). (D) Final resection about 3¼ years after the initial surgery presented with the histology of a full-blown cell-rich tumor recurrence. (E and F) HIF-2α staining at different time points: Note that there is markedly higher HIF-2α expression in the tissue from the first recurrence (prior to O~2~-O~3~) (E) than in the final resection immediately following O~2~-O~3~ treatment (F). HIF-2α is particularly expressed in blood vessels prior to O~2~-O~3~ (black arrowheads). No differences between biopsies were observed for HIF-1α immunostaining (data not shown). HIF, hypoxia-inducible factor.](ol-16-05-5813-g00){#f1-ol-0-0-9397}

![Tumor size was calculated by semi-automated contouring of tumor borders on each T1 weighted-slice (post gadolinium) in cm^3^, and additionally maximum 2D diameter in mm.](ol-16-05-5813-g01){#f2-ol-0-0-9397}

![Sagittal and transverse MR T1-weighted images post gadolinium images of Patient No. 1 (illustrative case) at diagnosis (A), at progression six months after the initial biopsy and standard radio-chemotherapy (B), and following tumor resection and implantation of the reservoir for the intra-tumoral O~2~-O~3~ treatment (C).](ol-16-05-5813-g02){#f3-ol-0-0-9397}

![Sagittal MR T1-weighted images post gadolinium images of Patient No. 3 in whom the O~2~-O~3~ treatment was started following the initial surgery and diagnosis of (A) GB. Six months later, some contrast enhancement was still visible (B), that was not apparent four years following diagnosis (C).](ol-16-05-5813-g03){#f4-ol-0-0-9397}

###### 

Detailed patient characteristics.

                                                              Patient no.                                                                                                                                                                                                                                                                  
  ----------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- ---------------------
  Sex                                                         M                                                    F                                                    F                                                     M                                                      M                                                     
  Age (years)                                                 59                                                   68                                                   48                                                    31                                                     45                                                      48 (31--68)
  Karnofsky index (%)                                         50                                                   70                                                   90                                                    80                                                     90                                                      80 (50--90)
  Initial surgery                                             Biopsy                                               Biopsy                                               Complete tumor resection and reservoir implantation   Partial tumor resection                                Subtotal tumor resection                              
  Surgery at progression                                      Partial tumor resection and reservoir implantation   Partial tumor resection and reservoir implantation                                                         Subtotal tumor resection and reservoir implantation    Complete tumor resection and reservoir implantation   
  Histology (WHO 2016)                                        Glioblastoma, *IDH*-wildtype, WHO grade IV           Glioblastoma, *IDH*-wildtype, WHO grade IV           Glioblastoma, *IDH*-wildtype, WHO grade IV            (Secondary) glioblastoma, *IDH*-mutant, WHO grade IV   Glioblastoma, *IDH*-wildtype, WHO grade IV            
  *MGMT* promoter methylation                                 5%                                                   10%                                                  5%                                                    25%                                                    Negative (\<3%)                                         5% (3--25)
  *IDH* mutation                                              WT                                                   WT                                                   WT                                                    Mutant                                                 WT                                                    
  Ki67 proliferation index                                    20%                                                  n.a. (Infiltrative rim, no solid tumour core)        40%                                                   30%                                                    30%                                                   30% (20--40)
  p53 nuclear accumulation                                    Some                                                 0 (negative)                                         10% (heterog.)                                        70--80%                                                10%                                                   10% (0--75)
  Radiotherapy                                                50 Gy+10 Gy boost                                    No                                                   50 Gy+10 Gy boost                                     50 Gy+10 Gy boost                                      46 Gy+14 Gy boost                                     
  Chemotherapy                                                Temozolomide                                         Temozolomide                                         Temozolomide                                          Temozolomide                                           Temozolomide                                          
  Second-line chemotherapy                                    PCV                                                  PCV                                                  None                                                  None                                                   PCV                                                   
  Tumor volume at diagnosis, cm^3^                            10.5                                                 13.4                                                 44.1                                                  136                                                    29.4                                                  29.4 (10.5--136)
  Tumor volume at progression before O~2~-O~3~, cm^3^         29.3                                                 5.50                                                 n/a                                                   12.7                                                   Frontal, 8.63; parietal, 11.6                         16.5 (5.50--29.3)
  Tumor volume at start of O~2~-O~3~, cm^3^                   13.3                                                 0                                                    3.03                                                  0                                                      Frontal, 1.09; parietal, 5.50                         3.0 cm^3^ (0--13.3)
  Tumor volume at progression after O~2~-O~3~, cm^3^          25.5                                                 14.4                                                 n/a                                                   27.5                                                   Frontal, 5.8; parietal 65.2,                          26.5 (14.4--71.0)
  Progression-free survival, months                           38                                                   12                                                   53                                                    29                                                     10                                                      6 (4--53)
  Overall survival, months                                    40                                                   46                                                   53                                                    31                                                     16                                                      40 (16--53)
  Number of O2-O3 applications                                31                                                   3                                                    44                                                    27                                                     10                                                      27 (3--44)
  Procedure related complications                             Infection                                            --                                                   --                                                    --                                                     Haemorrhage                                           
  Interval between diagnosis and start of O~2~-O~3~, months   6                                                    9                                                    0                                                     4                                                      4                                                       4 (4--9)
  Survival following O~2~-O~3~, months                        33                                                   37                                                   50                                                    27                                                     11                                                    34 (12--53)

*MGMT*, O-6-methylguanine-DNA-methyltransferase; *IDH*, isocitrate dehydrogenase; Ki67, Mib-1 antigen; p53, BP53-12 antigen; O~2~, oxygen; O~3~, ozone; M, male; F, female; WT, wild-type; Gy, Gray; n/a, not available.

###### 

Clinical and experimental studies utilizing ozone.

  Author (year)               Study type                      Disease                                          Route of O~3~ application                                       Unit of analysis                Sample size          Findings                                                                                                                                                                                   (Refs.)
  --------------------------- ------------------------------- ------------------------------------------------ --------------------------------------------------------------- ------------------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------
  Batinjan *et al*, 2014      Case report                     Radiation induced osteonecrosis of the jaw       Alveolus ozoning                                                Patients                        N=1                  O~3~ improved wound healing                                                                                                                                                                ([@b16-ol-0-0-9397])
  Brozoski *et al*, 2014      Case series                     Biphoshonate induced osteonecrosis of the jaw    Irrigation with aqueous O~3~ 4 mg/l                             Patients                        N=2                  O~3~ improved wound healing                                                                                                                                                                ([@b17-ol-0-0-9397])
  Clavo *et al*, 2013         Case series                     Hemorrhagic radiation-induced proctitis          Rectal insufflation of O~2~-O~3~, O~3~ oil                      Patients                        N=17                 O~2~-O~3~ reduced endoscopic treatments (p\< 0.063), reduced blood loss (p\<0.001), reduced median toxicity grades (p\<0.001)                                                              ([@b18-ol-0-0-9397])
  Clavo *et al*, 2005         Case report                     Radiation-induced cystitis                       Intra-vesicular instillation of O~3~ at 20--25 g/ml             Patients                        N=1                  O~3~ resulted in control of hematuria                                                                                                                                                      ([@b19-ol-0-0-9397])
  Ripamonti *et al*, 2011     Prospective phase I--II study   Osteonecrosis of the jaw                         O~3~ oil suspension for 10 min for 10 local applications        Patients                        N=10                 O~3~ induced spontaneous expulsion in 8 and new bone formation in 2 patients; in 2 patients no residual bone lesions were observed                                                         ([@b20-ol-0-0-9397])
  Ripamonti *et al*, 2012     Case series                     Osteonecrosis of the jaw                         O~3~ insufflation once daily for each pathological area         Patients                        N=24                 O~3~ response rate was 75.0% (95% CI, 53.3--90.2%) in intention to treat and 100% (95% CI, 81.5--100%) in per protocol analysis. No relapse (follow-up mean 18 months, range 1--3 years)   ([@b21-ol-0-0-9397])
  Petrucci *et al*, 2007      Case series                     Biphoshonate induced osteonecrosis of the jaw    O~3~ once daily, 7 days before to 7 days after surgery          Patients                        N=12                 O~3~ resulted in 8 (75%) in resolution of osteonecrosis, in 4 patients (25%) in improvement with persistence of lesio                                                                      ([@b22-ol-0-0-9397])
  Herbert *et al*, 1996       Basic research                  Lung tumor incidence                             Inhalation (O~3~ at 0.12, 0.5, 1.0 ppm, 6 h/day for lifetime)   Mice                            N=100 total          O~3~ induced at the highest concentration the tumor incidence in female mice                                                                                                               ([@b23-ol-0-0-9397])
  Ichinose *et al*, 1992      Basic research                  Lung tumor incidence                             Inhalation (O~3~ at 0.05 ppm for 13 months)                     Rats                            N=36 per group       O~3~ at ambient level showed some tumor-enhancing action, although the effect was small                                                                                                    ([@b24-ol-0-0-9397])
  Donaldson et al, 1991       Basic research                  Lung tumor incidence                             Inhalation (O3 at 0.2--0.8 ppm, 7 h/day for up to 4 days)       Rats                            N=3, 13 groups       O3 at higher doses decreased macrophages and increased neutrophils on day 1 and 2; macrophages were larger                                                                                 ([@b25-ol-0-0-9397])
  Hoogervorst *et al*, 2003   Basic research                  Lung tumor incidence                             Inhalation (O~3~ at 0.08 ppm for 13 weeks)                      DNA repair-deficient Xpa mice   N=20 per group       O~3~ induced cell proliferation and, dependent on the mouse strain, a slight increase in tumor incidence                                                                                   ([@b26-ol-0-0-9397])
  Witschi *et al*, 1993       Basic research                  Lung tumor incidence                             Inhalation (O~3~ at 0.8 ppm, 23 h/day for 24 weeks)             Hamsters                        N=80 total           O~3~ increased the tumor incidence, but reduced the incidence following treatment with the carcinogen N-nitrosodiethylamine                                                                ([@b27-ol-0-0-9397])
  Last *et al*, 1987          Basic research                  Lung tumor incidence                             Inhalation (O~3~ at 0.4 to 0.8 ppm, 7 h/day for 18 weeks)       Different mice strains          N=31--37 per group   O~3~ at higher concentrations increased tumor incidence; following treatment with the carcinogen urethane, O~3~ inhibited the tumor development in A/J mice                                ([@b28-ol-0-0-9397])
  Kiziltan *et al*, 2015      Basic research                  Peritoneal carcinomatosis                        Intra-peritoneal O~3~ at 20 or 40 µg/ml ± radiotherapy          Mice                            N=60 total           O~3~ and radiotherapy, either separately or concurrently, increased the survival rates                                                                                                     ([@b30-ol-0-0-9397])
  Schulz *et al*, 2008        Basic research                  Head and neck squamous cell carcinoma            Intra-peritoneal O~2~-O~3~ insufflation                         Rabbits                         N=59 total           O~2~-O~3~ induced significant tumor regression; effect reversed by immune suppression (dexamethasone, cyclosporine A)                                                                      ([@b31-ol-0-0-9397])
  Rossmann *et al*, 2014      Basic research                  Papillomavirus-associated head and neck cancer   Intra-peritoneal O~2~-O~3~ insufflation                         Rabbits                         N=20 total           O~2~-O~3~ resulted in tumor eradication by immune 'memory' cells, and a significant increase of peripheral white blood cells and CD3+ T cells                                              ([@b32-ol-0-0-9397])

O~2~, oxygen; O~3~, ozone; ppm, parts per million; CI, confidence interval.
